CanSino Biologics Inc. (CANSINOBIO) will convene its 2025 Annual General Meeting on 10 June 2026 at 1:30 p.m. in Tianjin. Shareholders of record are entitled to vote in person or by proxy, with proxy forms due at Computershare Hong Kong Investor Services by 1:30 p.m. on 9 June 2026.

Ordinary business covers the 2025 Board work report, the Group’s 2025 annual report, a profit-distribution proposal and a three-year (2026-2028) dividend-and-return plan. Investors will also decide on re-appointing Deloitte Touche Tohmatsu as both onshore and offshore auditor for 2026, renewing bank credit lines, authorising foreign-exchange hedging, acknowledging an uncovered deficit that equals or exceeds one-third of paid-up capital, purchasing directors’ and officers’ liability insurance, and adopting a remuneration management system for directors and senior management.

Special resolutions ask shareholders to grant the Board a general mandate to issue up to 20 percent of existing A and/or H share capital—including any sale of Treasury H shares—and a simplified-procedure mandate to issue additional A shares. The meeting will also vote on a 10 percent share-repurchase mandate, authority to issue onshore and offshore debt instruments, and a comprehensive update to the Articles of Association and related procedural rules.

Approval or rejection of these mandates will shape CANSINOBIO’s financing flexibility for equity, debt and treasury operations, while the uncovered deficit item signals the need for shareholder acknowledgement of current capital status ahead of any future distribution decisions. Shareholders have one vote per fully paid share.